In a season where a number of five/four U.S. Supreme Court Decisions have left the country divided or dubious over the ability of the court to issue decisions compatible with a modernized America, the unanimous decision in the Myriad Genetics Inc. patent case has been both wise and should contribute to our ongoing bio-medical research progress. The case was brought because The Myriad Genetics Company was in the process of treating the BRCA1 and BRCA2 genes as something they had patented. A woman who has a strong family history of breast cancer and has one of the BRCA genes has about a 50% to 80% likelihood of developing breast cancer, as opposed to the average 12% or 13% risk. Testing for this gene, or an increasing number of potentially diagnostic genes, is a major part of diagnostic and treatment improvement in the coming decades. Sophisticated observers of our health care system look on the use of genomics, if used properly, as one of the major roads to improving care, and potentially cutting costs.
A problem in this area, if pharmaceutical, or medical diagnostic companies could patent genes as they were discovered, would be higher costs and potentially limited access to their more general use. Of course, as in many legal cases, courts could go too far and if all research in medical genetics were outside the processes that could be patented, financial incentives for medical research in this area could be dramatically stifled. In this instance, the court was very wise, in differentiating between the genes themselves—part of our basic biochemistry—and techniques for analyzing our genome and ultimately ways to modify the genes. The court, while ruling that the genes, themselves, were in the public domain, the researchers could continue to patent their newly discovered or improved techniques for isolating or modifying these genes. That should have no inhibitory effect on this major area of research.
I see a future with a potential for certain of our rarer, single gene, inherited, disorders such as cystic fibrosis or sickle cell anemia, to ultimately be modified as the person develops. I also believe, with a greater overall effect on health statistics, the impact on major multiple gene diseases such as atherosclerosis, or certain auto-immune disorders, in diagnosis, prevention and treatment, will be left intact. The court’s thoughtfulness in this case has made the economics of accessibility as well as encouragement of research possible by its balanced Myriad decision.
U.S. Strikes in Iran: the Urgent Need for Congressional Oversight On June 21st, President Trump abruptly attacked Iranian nuclear facilities with American bombers. The next day, he abruptly announced a
July 3, 2025 (Washington, D.C.) – Congressman Don Beyer (D-VA) this morning delivered the following remarks on H.R. 1, aka the One Big Ugly Bill Act, during debate on the measure: “From
On Saturday, June 28, Congressman Don Beyer and Virginia Delegate Marcus Simon were among the panelists for a Town Hall hosted by the NAACP branches in Fairfax, Arlington, and Alexandria.
Growing up in post-World War II America presented few options for young women past high school. College graduates could aspire to be elementary school teachers or nurses but, once married,
Legitimate news organizations need grass roots support like never before, and that includes your Falls Church News-Press. For more than 33 years, your News-Press has kept its readers informed and enlightened. We can’t continue without the support of our readers. This means YOU! Please step up in these challenging times to support the news source you are reading right now!
A Sensible Supreme Court Decision for Health Care Research
Dr. Thomas Connally
In a season where a number of five/four U.S. Supreme Court Decisions have left the country divided or dubious over the ability of the court to issue decisions compatible with a modernized America, the unanimous decision in the Myriad Genetics Inc. patent case has been both wise and should contribute to our ongoing bio-medical research progress. The case was brought because The Myriad Genetics Company was in the process of treating the BRCA1 and BRCA2 genes as something they had patented. A woman who has a strong family history of breast cancer and has one of the BRCA genes has about a 50% to 80% likelihood of developing breast cancer, as opposed to the average 12% or 13% risk. Testing for this gene, or an increasing number of potentially diagnostic genes, is a major part of diagnostic and treatment improvement in the coming decades. Sophisticated observers of our health care system look on the use of genomics, if used properly, as one of the major roads to improving care, and potentially cutting costs.
A problem in this area, if pharmaceutical, or medical diagnostic companies could patent genes as they were discovered, would be higher costs and potentially limited access to their more general use. Of course, as in many legal cases, courts could go too far and if all research in medical genetics were outside the processes that could be patented, financial incentives for medical research in this area could be dramatically stifled. In this instance, the court was very wise, in differentiating between the genes themselves—part of our basic biochemistry—and techniques for analyzing our genome and ultimately ways to modify the genes. The court, while ruling that the genes, themselves, were in the public domain, the researchers could continue to patent their newly discovered or improved techniques for isolating or modifying these genes. That should have no inhibitory effect on this major area of research.
I see a future with a potential for certain of our rarer, single gene, inherited, disorders such as cystic fibrosis or sickle cell anemia, to ultimately be modified as the person develops. I also believe, with a greater overall effect on health statistics, the impact on major multiple gene diseases such as atherosclerosis, or certain auto-immune disorders, in diagnosis, prevention and treatment, will be left intact. The court’s thoughtfulness in this case has made the economics of accessibility as well as encouragement of research possible by its balanced Myriad decision.
Recent News
Senator Saddam Salim Richmond Report
U.S. Strikes in Iran: the Urgent Need for Congressional Oversight On June 21st, President Trump abruptly attacked Iranian nuclear facilities
Beyer Floor Remarks Opposing H.R. 1
July 3, 2025 (Washington, D.C.) – Congressman Don Beyer (D-VA) this morning delivered the following remarks on H.R. 1, aka the One
Beyer, Simon Speak at Tri-Branch NAACP Town Hall
On Saturday, June 28, Congressman Don Beyer and Virginia Delegate Marcus Simon were among the panelists for a Town Hall
A Penny for Your Thoughts 7-3-2025
Growing up in post-World War II America presented few options for young women past high school. College graduates could aspire
Cult Century: 1970s Roots Of Trumpism, Part 7 of 25
The U.S. Senate approval this week has been of perhaps the most heinous bill ever, stealing from the poor to
Rev. M. Davies Kirkland Says Thank You City of Falls Church
byThe Rev. M. Davies Kirkland Pastor, Dulin United Methodist Church (Ed. Note – The Rev. Kirkland’s 25 year ministry at
Stories that may interest you
Senator Saddam Salim Richmond Report
U.S. Strikes in Iran: the Urgent Need for Congressional Oversight On June 21st, President Trump abruptly attacked Iranian nuclear facilities with American bombers. The next day, he abruptly announced a
Beyer Floor Remarks Opposing H.R. 1
July 3, 2025 (Washington, D.C.) – Congressman Don Beyer (D-VA) this morning delivered the following remarks on H.R. 1, aka the One Big Ugly Bill Act, during debate on the measure: “From
Beyer, Simon Speak at Tri-Branch NAACP Town Hall
On Saturday, June 28, Congressman Don Beyer and Virginia Delegate Marcus Simon were among the panelists for a Town Hall hosted by the NAACP branches in Fairfax, Arlington, and Alexandria.
A Penny for Your Thoughts 7-3-2025
Growing up in post-World War II America presented few options for young women past high school. College graduates could aspire to be elementary school teachers or nurses but, once married,